The first of its kind! Dechi Pharmaceuticals has submitted applications for the listing of new anti-cancer drugs in several Asia Pacific markets

· For the treatment of adult patients with recurring refractic multiple myeloma (rrMM), who have received at least four-line treatment including two protease inhibitors, two immunomodulants and CD38 monoclonal antibodies; For patients with multiple myeloma who have received at least first-line treatment in the past in the combined treatment of boroniczomi and dexamisson; Used to treat adult patients with recurring recurring refractic large B-cell lymphoma (rrDLBCL), who have previously received at least second-line treatment for rrDLBCL (including conversion from folytic lymphoma).
, the Australian Medical Supplies Authority accepted a new drug listing application from Deki Pharmaceuticals on December 2.
, Dechi Pharmaceuticals also submitted Xpovio's NDA to the Hong Kong Department of Health for the treatment of adult rrMM patients.
, the product was awarded orphan drug eligibility in South Korea for the treatment of adult rrMM patients and rrDLBCL patients.
press release, Xpovio is the first and only oral selective nuclear output inhibitor of its kind, developed by Dechi Pharmaceuticals in collaboration with Karyopharm Therapeutics.
July 2019, the FDA approved the drug as a combined low-dose dexamison for the treatment of rrMM patients.
June 2020, the FDA again approved it as a single-drug oral therapy for the treatment of rrDLBCL patients.
addition, Xpovio has conducted a number of mid- and post-clinical trials for multiple solid tumor adaptations, including liposarcoma and endometrial cancer.
, Xpovio's Phase 3 SEAL study for patients with liposarcoma has recently yielded positive data, and phase 3 SIENDO studies for the treatment of endometrial cancer patients have passed the planned medium-term ineffectiveness analysis.
in China, Deqi Pharmaceuticals is conducting Phase 2 registered clinical studies of Xpovio for recurring multiple myeloma, as well as phase 2 registered clinical studies for recurring diffuse large B-cell lymphoma.
same time, Deki Pharmaceuticals initiated a clinical study of Xpovio for the treatment of exocytocyte lymphoma, NK/T cell lymphoma, and non-small cell lung cancer with KRAS mutations.
: Deki Pharmaceuticals has submitted a new drug listing application for XPOVIO® (Selinexor) in several Asia Pacific markets for the treatment of recurring multiple myeloma and diffuse large B-cell lymphoma. Retrieved Dec 4, 2020, from Source: Medical Mission Hills